EPA:PERP 8 February 2026

June 12, 2026, 6:18 PM EDT. Alumis Inc. (ALMS) shares surged 15.55% to close at $24.15 on Nasdaq Friday, with volumes more than doubling to 2.25 million shares. Investors are focusing on upcoming catalysts, notably Phase 2b LUMUS trial data for lupus expected in Q3 and the planned New Drug Application (NDA) filing for psoriasis in Q4 2026. Alumis, a late-stage biopharma developing oral TYK2 inhibitor envudeucitinib for inflammatory diseases, posted a $93.1 million net loss in Q1 and has no approved products or current sales. The stock remains high risk but draws bullish sentiment from analyst price targets well above current levels and a strong cash position to fund operations through late 2027. CEO Martin Babler reaffirmed the NDA filing timeline amid positive psoriasis trial results showing significant skin clearance.